Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation

Liang Liu, Joel B. Berletch, Jessica G. Green, Mitchell S. Pate, Lucy G. Andrews, and Trygve O. Tollefsbol

1Department of Biology, 2Center for Aging, and 3Comprehensive Cancer Center, University of Alabama-Birmingham, Birmingham, Alabama

Abstract
Human promyelocytic leukemia HL60 cells display high telomerase activity, a phenotype related to their immortal status. All-trans retinoic acid (ATRA) is a clinically effective cytodifferentiating agent. To understand the mechanism underlying ATRA-induced cytodifferentiation, we did a kinetic analysis of the role of ATRA in inhibiting telomerase in HL60 cells. Our studies indicate that telomerase inhibition by ATRA occurred relatively early after treatment of HL60 cells due to a rapid decrease in hTERT gene expression. More importantly, however, we found through monitoring the expression of CD11b, a marker for granulocytic differentiation of HL60 cells, that down-regulation of telomerase preceded the differentiation of HL60 cells. These observations suggest that the hTERT gene may be a primary target of ATRA regulation of cellular differentiation and the anti-leukemia activity of ATRA may be mediated by its ability to induce the differentiation of the promyelocytic leukemia cells through down-regulation of the hTERT gene.

Introduction
Human promyelocytic leukemia HL60 cells are derived from peripheral blood leukocytes of a patient with acute promyelocytic leukemia, which is a subtype of myeloid leukemia characterized by the accumulation of cells blocked at the promyelocytic stage (1). Retinoids are natural compounds structurally related to vitamin A. They play essential roles in normal developmental processes such as cell proliferation, differentiation, and apoptosis. Retinoids also possess pharmacologic properties as chemopreventive agents and are often used in clinical treatment of cancers including acute promyelocytic leukemia, laryngeal papilloma, and oral leukoplakia lesions (2, 3). The most extensively studied retinoids in cancer medicine include all-trans retinoic acid (ATRA), 9-cis retinoic acid, and 13-cis retinoic acid. ATRA is one of the most biologically active retinoids, and several clinical studies have established that ATRA can induce differentiation of leukemia cells and remission through an unknown mechanism in almost all patients (4). This has led to the development of ATRA therapies for the prevention and treatment of various human cancers such as renal cell carcinoma, breast cancer, prostate cancer, and other malignancies (3).

Recently, extensive interest has been focused on the aberrant regulation of telomerase activity in tumorigenesis. Telomerase is a reverse transcriptase that synthesizes telomeric repeats at the ends of chromosomes. The length of telomeric repeats shortens gradually with cell division, and this telomere shortening is associated with cellular senescence. Two major components of human telomerase have been identified: the RNA template and the reverse transcriptase (hTERT). The RNA template is expressed in both normal and cancerous tissue, whereas hTERT is often detectable in cancerous cells but not in normal somatic cells (5). The mRNA level of hTERT often correlates positively with telomerase activity and has thus been considered as the major determinant of telomerase activity (6). Telomerase is present in human stem cells, progenitor cells, and germ cells but is undetectable in the vast majority of adult somatic tissues (7). Although alternative mechanisms of maintaining telomere length have been reported (8), most tumors examined thus far seem to employ telomerase activation as a means to escape senescence and retain high proliferative potential (9).

High telomerase activity has been observed in HL60 cells, a phenotype related to their immortal status (9, 10). HL60 cells display distinct morphologic and histochemical commitment toward myeloid differentiation. Previous studies have established that HL60 cells respond well to cytodifferentiating reagents like DMSO and 1,25α-dihydroxyvitamin D3 and have the potential to give rise to monocytes and macrophage cells (11–13). Addition of ATRA to the growth medium often induces differentiation of these progenitors to neutrophils. The mechanism of this differentiating function by ATRA treatment is not yet understood, although existing evidence indicates that telomerase activity may be somehow linked with this cytodifferentiating activity (14). The current study addresses the molecular pathways involved in neutrophil differentiation of HL60 cells by ATRA treatment. Our studies indicate that ATRA down-regulates hTERT and thus...
telomerase activity in early differentiation, and this process precedes cellular differentiation of the promyelocytic cells, indicating that ATRA may exert its anticarcinogenic effects through down-regulation of the hTERT gene.

Materials and Methods

Cell Culture and Proliferation Assessment

HL60 cells (American Type Culture Collection, Manas-ssas, VA) were grown in suspension culture as described previously (15). For all experiments, the HL60 cells were seeded at 4 x 10^5 cells/mL in fresh medium and ATRA (Sigma Chemical Co., St. Louis, MO) was added to 1 μmol/L final concentration. Control cells were grown in parallel under the same conditions as treated cells but without the addition of ATRA. Morphologic changes in the cells were recorded using a Nikon Coolpix990 digital camera (Nikon, Tokyo, Japan). The HL60 cells used for growth curve studies were grown for a total of 12 days. Cell counting was done in parallel cultures, and cells were counted on days 0, 3, 6, 9, and 12 following ATRA treatment using trypan blue (0.25%) to stain for monitoring the viability of the cells, which were counted on a Neubauer hemacytometer.

Fluorescence-Activated Cell Sorting Analysis of CD11b Expression

Fluorochrome conjugates of monoclonal antibody against human CD11b antigen, the maturation marker for granulocytes, were used to detect CD11b expression in ATRA-treated and nontreated HL60 cells following the protocol from the manufacturer (Sigma Chemical). Briefly, ~0.5 x 10^5 cells were harvested, washed twice with cold PBS, and incubated with antibody (2 μg) conjugated with FITC for 30 minutes at room temperature. After incubation, the cells were washed twice with diluent solution (PBS containing 1% bovine serum albumin and 0.1% NaN3), fixed with 2% paraformaldehyde, and analyzed on a Becton Dickinson FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ). The fluorescence intensity of the viable cells (identified by their light scattering characteristics) was analyzed using CellQuest software. Nontreated HL60 cells incubated only with diluent solution were included as control to set the gating threshold value (0.9%).

RNA Extraction, cDNA Synthesis, and PCR Amplification

Total cellular RNA was purified using the RNeasy Mini kit (Qiagen, Valencia, CA). Extracted RNA was digested with RQI RNase-free DNase (2 units, Promega, Madison, WI) to remove any DNA contamination. After digestion, DNase was removed by phenol-chloroform extraction. RT-PCR was done as described previously (16) with slight modifications. RNA (~2 μg) was reverse transcribed in 20 μL of final reaction volume using the SuperScript premplification system for first-strand cDNA synthesis (Life Technologies, Rockville, MD). From this reaction, cDNA (1.5 μL) was used as the template for PCR reactions with a primer set specific to a 219-bp fragment of the hTERT gene coding region: forward 5’-GACTCGACAC-GTTCCACTAC-3’ and reverse 5’-GACACACATT-CACAGGTCG-3’. Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was done as an internal control as described previously (16). After 32 cycles of amplification, PCR products were resolved on an 1.5% agarose gel and analyzed using the Kodak 1D 3.6.1 image software (Eastman Kodak Company, Rochester, NY).

Quantitative real-time PCR was done on cDNA from ATRA-treated and nontreated cells by use of the ABI Prism 7900 Sequence Detection System (PE Applied Biosystems, Foster City, CA) following the Assays-on-Demand protocol. GAPDH was included as a control reference gene to normalize the amount and the quality of cDNA. Primers for hTERT and GAPDH were preoptimized and mixed with TaqMan MGB probe (FAM dye labeled, PE Applied Biosystems). Quantitative data were analyzed using the Sequence Detection System software version 2.1 (PE Applied Biosystems). This relative quantification is given by the ratio of the mean value of the target gene (hTERT) to the mean value of the endogenous control (GAPDH) gene in each sample.

Telomeric Repeat Amplification Protocol Assay

The telomeric repeat amplification protocol (TRAP) assay was done as described previously (17). Briefly, cells were harvested and lysed in CHAPS lysis buffer. The lysate was centrifuged for 20 minutes at 12,000 x g at 4°C, and the supernatant (2 μL) was used in PCR amplification according to the manufacturer’s protocol (Intergen, Burlington, MA). In addition, supernatant (10 μL) from each sample was incubated at 94°C for 10 minutes to serve as a heat inactivation control. PCR was done at 30°C for 30 minutes followed by 38 cycles at 94°C for 30 seconds, 59°C for 30 seconds, and 72°C for 1 minute. The reaction is finished at 55°C for a 25-minute extension step. An internal control together with a specific primer was added to the reaction mixture to monitor the efficiency of PCR. To determine whether ATRA directly inhibits telomerase enzyme activity in cell-free system, protein extracts from control HL60 cells were incubated with various concentrations of ATRA (0.2, 1, and 5 μmol/L) at 37°C for 10 minutes prior to the standard TRAP assay. The PCR products were electrophoresed on a 10% nondenaturing polyacrylamide gel and stained with SYBR Green (Molecular Probes, Eugene, OR).

Results

Changes in Morphology and Proliferation Rate of HL60 Cells in Response to ATRA Treatment

When suspension cultures of HL60 cells were treated with ATRA, the cells displayed gradual morphologic changes toward neutrophil differentiation as indicated by the segmented nucleus (Fig. 1A–C) within 12 days, whereas the nontreated control cells maintain stable morphology and proliferative rate throughout the experiments (data not shown). In addition to the changes in nuclear structure, a striking feature observed was that the treated cells began to cluster together to form cell clumps from the single cell suspension. The size of the cell clumps increased...
Figure 1. A to E, morphologic changes following addition of retinoic acid in the growth medium. A, nontreated control cells (identical morphologies of nontreated cells were observed throughout the experiment; thus, only one control for day 12 was presented for all retinoic acid experiments). B to E, morphologies of the cells following 3, 6, 9, and 12 days of retinoic acid treatment, respectively. Magnification, ×200 (A to E). F and G, graphic presentations of growth kinetics of HL60 cells following addition of retinoic acid in the growth medium: total number of cells (F) and percentage of dead cells during retinoic acid treatment (G). Similar results were obtained from independent counting. Bars, SE. H, representative fluorescence-activated cell sorting results showing the gradual expression of the CD11b adhesive molecule during development of neutrophils. Percentage values, percentage of CD11b-positive HL60 cells determined by the fluorescence-activated cell sorting. FITC characteristics of nontreated control (upper panel) and retinoic acid–treated (lower panel) cells at different experimental days.
with the number of treatment days. By day 12 in the presence of ATRA, most of the cells were growing in clusters (Fig. 1A–E). Following the maturation of HL60 cells, a decrease in the proliferation rate was clearly visible by day 6, which was accompanied by an increase in the number of dead cells (Fig. 1F and G). Spontaneous cell death of the untreated cells was also observed, but this process did not interfere with log-phase proliferation of the cells. Cell clumps were not observed in the control cells. These findings show that, after treatment with ATRA, promyelocytic leukemia cells slowed down in proliferation and gradually differentiated toward cells that have characteristics of neutrophils. ATRA-induced differentiation led to growth inhibition and eventual death of the differentiated cells.

**Gradual Increase in Expression of CD11b in ATRA-Treated HL60 Cells**

Expression of the CD11b antigen was monitored every 3 days during ATRA-induced differentiation of the HL60 cells. Cells were stained with FITC-conjugated mouse monoclonal antibody against human CD11b after 3, 6, 9, and 12 days of ATRA treatment. Nontreated cells were grown in parallel and included as controls. A basal level of CD11b expression was present in nontreated control cells (Fig. 1H, upper panel), reflecting the fact that these cells underwent spontaneous maturation that was followed by apoptosis as indicated from the growth kinetic analysis in Fig. 1F and G. Following ATRA treatment, a gradual increase in CD11b expression can clearly be seen from the fluorescence-activated cell sorting data depicted in Fig. 1H (lower panel). By day 12, >90% of the cells expressed CD11b, the adhesion molecule most likely responsible for the cell clumps in the culture as shown in Fig. 1E. These kinetics of CD11b expression were consistent with the observed gradual morphologic changes in the ATRA-treated cells, confirming that ATRA-induced differentiation tended to be a gradual process occurring in terms of days rather than hours.

**Significant Loss of Telomerase Activity following ATRA Treatment of HL60 Cells**

To address whether telomerase activity was involved in the differentiation process of HL60 cells, we did TRAP assays on nontreated control and ATRA-treated HL60 cells at the aforementioned days following addition of ATRA to the medium. As illustrated in Fig. 2A, the presence of telomerase activity was shown by the 6-bp ladder banding pattern that started at 61 bp. A 56-bp internal control band to monitor the PCR efficiency was visible in every sample.
Comparing threshold cycle values between the number of threshold PCR cycles prior to reaching amplification plateau in that Detection System software (PE Applied Biosystems).

After only 3 days of treatment, despite the dramatic decrease in telomerase activity in response to ATRA treatment, which has not been discussed before. The expression of the CD11b adhesion molecule has been frequently employed as a maturation marker for HL60 cells in response to drug-induced differentiation. Previous studies reported that >90% of cells became CD11b positive following 2 to 3 days of treatment with DMSO or 1,25a-dihydroxyvitamin D3, which had a more acute and rapid differentiation effect than ATRA with maturation of HL60 cells toward monocytes and macrophages (12, 13). Our studies showed that differentiation of HL60 by ATRA took longer than that reported previously for DMSO and 1,25a-dihydroxyvitamin D3 as indicated by the gradually increased expression of CD11b. The lineage of differentiation may affect the pace of CD11b synthesis. Alternatively, cells may be relatively less sensitive in response to ATRA treatment because physiologic levels of retinoids are required during normal development and growth. Adaptive systems may have evolved to tolerate transient increases of retinoids at the pharmacologic level but will eventually succumb to an extended presence of increased levels of retinoids. This lower sensitivity to ATRA treatment is also consistent with a protracted change in morphology following the initial treatment of cells as we discussed above.

In contrast to the slow onset of synthesis of CD11b, telomerase activity is more rapidly decreased in differentiating HL60 cells in response to ATRA treatment as we discussed above.

Control cells (no retinoic acid treatment) clearly displayed the 56-bp control band and a ladder of PCR products with 6-bp increments (more than seven bands), which indicated a high level of telomerase activity in the undifferentiated HL60 cells. With the addition of ATRA in the growth medium, however, telomerase activity decreased rapidly and was almost nondetectable by day 9 (Fig. 2A-A). All samples that were subjected to heat inactivation displayed no telomerase activity, which confirmed that the observed telomerase activity was indeed of endogenous origin. When cellular protein extracts from telomerase-positive control HL60 cells were directly incubated with various concentrations of ATRA (0.2, 1, and 5 μmol/L), there was no obvious loss of telomerase activity observed (Fig. 2A-B), which indicates that ATRA does not directly inhibit telomerase protein activity.

### Loss of Telomerase Activity Is Preceded by a Rapid Decrease in hTERT Expression

Telomerase activity is closely correlated with hTERT expression. To confirm that a decrease in telomerase activity was indeed due to down-regulation of hTERT mRNA expression, we did RT-PCR to assess the expression status of the hTERT gene during differentiation of HL60 cells in a similar manner as our analysis using the TRAP assay. As shown in Fig. 2B-A, the control cells possessed high levels of hTERT mRNA as indicated by the intense band at 219 bp. The mRNA level decreased rapidly by day 3 and was almost undetectable by day 6 and later. Amplification of the internal control GAPDH gene, however, showed no change among ATRA-treated and control cells (Fig. 2B-A). To quantify the relative levels of hTERT mRNA in each sample, we did real-time PCR using the GAPDH gene as an endogenous control to normalize the amount and quality of cDNA. Relative expression levels of hTERT in each sample were derived from normalizing the threshold cycle value of hTERT against that of GAPDH (Table 1). The results shown in Fig. 2B-B indicate that ATRA triggered an ~100-fold decrease of hTERT mRNA after only 3 days of treatment. Despite the dramatic decrease in the level of hTERT mRNA in the cells after 3 days, the telomerase activity was still readily detectable by TRAP assay (Fig. 2A), suggesting that the hTERT protein remained stable and functional for a period of time after the rapid shutdown of the transcription of the hTERT gene, but that the enzymatic activity decreased within 3 days following down-regulation of the hTERT gene.

### Discussion

In this study, we showed that the differentiation process is more gradual than the down-regulation of telomerase activity in response to ATRA treatment, which has not been discussed before. The expression of the CD11b adhesion molecule has been frequently employed as a maturation marker for HL60 cells in response to drug-induced differentiation. Previous studies reported that >90% of cells became CD11b positive following 2 to 3 days of treatment with DMSO or 1,25a-dihydroxyvitamin D3, which had a more acute and rapid differentiation effect than ATRA with maturation of HL60 cells toward monocytes and macrophages (12, 13). Our studies showed that differentiation of HL60 by ATRA took longer than that reported previously for DMSO and 1,25a-dihydroxyvitamin D3 as indicated by the gradually increased expression of CD11b. The lineage of differentiation may affect the pace of CD11b synthesis. Alternatively, cells may be relatively less sensitive in response to ATRA treatment because physiologic levels of retinoids are required during normal development and growth. Adaptive systems may have evolved to tolerate transient increases of retinoids at the pharmacologic level but will eventually succumb to an extended presence of increased levels of retinoids. This lower sensitivity to ATRA treatment is also consistent with a protracted change in morphology following the initial treatment of cells as we discussed above.

In contrast to the slow onset of synthesis of CD11b, telomerase activity is more rapidly decreased in differentiating HL60 cells in response to ATRA treatment as we discussed above.

### Table 1. Representative average threshold cycle values derived from real-time PCR analysis of hTERT and GAPDH expression

<table>
<thead>
<tr>
<th>Samples</th>
<th>hTERT</th>
<th>GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>No retinoic acid</td>
<td>26.87</td>
<td>18.44</td>
</tr>
<tr>
<td>Retinoic acid, day 3</td>
<td>36.18</td>
<td>21.14</td>
</tr>
<tr>
<td>Retinoic acid, day 6</td>
<td>36.33</td>
<td>19.52</td>
</tr>
<tr>
<td>Retinoic acid, day 9</td>
<td>38.00</td>
<td>19.65</td>
</tr>
<tr>
<td>Retinoic acid, day 12</td>
<td>40.00</td>
<td>20.38</td>
</tr>
</tbody>
</table>

NOTE: Average threshold cycle values were derived from duplicated real-time PCR amplifications of hTERT and GAPDH expression. Each value indicates the average of hTERT values in each sample were derived from normalizing the amount and quality of cDNA. Relative expression levels of hTERT in each sample were derived from normalizing the threshold cycle value of hTERT against that of GAPDH (Sequence Detection System software (PE Applied Biosystems)).

### Table 2. Differences between kinetic loss of telomerase activity and kinetic increase in terminal cellular differentiation in differentiating HL60 cells

<table>
<thead>
<tr>
<th></th>
<th>% Loss of Telomerase Activity</th>
<th>% Terminal Cellular Differentiation</th>
<th>Differences between Columns 2 and 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>No retinoic acid</td>
<td>0</td>
<td>2.5</td>
<td>−2.5</td>
</tr>
<tr>
<td>Retinoic acid, day 3</td>
<td>26.7</td>
<td>20.9</td>
<td>5.8</td>
</tr>
<tr>
<td>Retinoic acid, day 6</td>
<td>68.5</td>
<td>39.3</td>
<td>19.2</td>
</tr>
<tr>
<td>Retinoic acid, day 9</td>
<td>100</td>
<td>68.6</td>
<td>31.4</td>
</tr>
<tr>
<td>Retinoic acid, day 12</td>
<td>100</td>
<td>91.2</td>
<td>8.8</td>
</tr>
</tbody>
</table>

NOTE: Percentage values in column 2 were derived from quantification of seven representative bands of the TRAP assay for each retinoic acid–treated sample as shown in Fig. 2A. The relative telomerase activity in each sample was determined by comparing the respective total value for each sample with nontreated control (No retinoic acid). Percentage values in column 3 were derived from fluorescence-activated cell sorting analysis of CD11b expression as shown in Fig. 1C.
HL60 cells and is almost nondetectable at 6 days of ATRA treatment. Obviously, the differentiation status of HL60 cells followed the diminished activity of telomerase, which suggests that telomerase activity may be essential in maintaining the undifferentiated stem cell status of HL60 cells (Table 2). Following diminished activity of telomerase, most of the promyelocytic cells became terminally differentiated. Whether down-regulation of telomerase activity was the sole cause of differentiation of HL60 cells remains to be further addressed; however, our findings assessing the kinetics of telomerase down-regulation and HL60 cellular differentiation suggest that telomerase may be a key player during the differentiation process.

As indicated by CD11b expression, a small percentage of cells seemed to be resistant to ATRA induction. Maturation of the HL60 cells did not reach completion even by day 12, suggesting that a heterogeneity of cell response to ATRA treatment may interfere with its clinical efficacy under certain circumstances. This heterogeneity may explain the clinical failure of cytodifferentiation therapy by ATRA as observed in some relapsed acute promyelocytic leukemia patients that leads to the resistance of those patients to further ATRA treatment (18). A recent study compared the effects of ATRA with those of 11-O-hydrophenanthrene, a new derivative of retinoic acid, on differentiation and apoptosis of HL60 cells (19). The results suggest that 11-O-hydrophenanthrene has more antiproliferative activity than ATRA and holds promise for future clinical applications. Further characterization of the molecular processes modulated by these agents will serve to better define their role in the prevention and treatment of human cancer and to tailor specific targeted therapies in combination with other compounds.

The hTERT gene may be a prime target gene subject to ATRA regulation because its level of expression was rapidly affected by ATRA administration as we have shown in this study. Reduced expression of hTERT led to diminished telomerase activity followed by maturation of the promyelocytic cells toward neutrophils (Fig. 3). These observations are consistent with our previous studies on human teratocarcinaoma cells (15, 16). Because ATRA has a large range of target genes involved in different biological processes (20), its therapeutic significance may pose potential harm to normal cells while being used as a general anticancer agent. Given the efficacy of diminished telomerase activity on growth inhibition of HL60 cells, drug development aimed specifically at telomerase activity, or its hTERT subunit by the use of RNA interference technology, may prove to be highly effective in future cancer therapies. Taken together, our results show that ATRA treatment of leukemia cells seems to involve down-regulation of hTERT expression and telomerase activity, contributing to a decrease in the proliferative potential of these cells. Ablation of telomerase activity may also contribute to the terminal differentiation of the promyelocytic cells. Further efforts are being undertaken to elucidate the inactivation mechanism of the hTERT gene on ATRA treatment.

Acknowledgments
We thank In-Kyung Kim for technical assistance.

References


Molecular Cancer Therapeutics

Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation

Liang Liu, Joel B. Berletch, Jessica G. Green, et al.


Updated version Access the most recent version of this article at: http://mct.aacrjournals.org/content/3/8/1003

Cited articles This article cites 20 articles, 8 of which you can access for free at: http://mct.aacrjournals.org/content/3/8/1003.full#ref-list-1

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/3/8/1003.full#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.